FAQ

darusentan

Known as: (+)-(S)-2-((4,6-dimethoxy-2-pyrimidinyl)oxy)-3-methoxy-3,3-diphenylpropionic acid, benzenepropanoic acid, alpha-((4,6-dimethoxy-2-pyrimidinyl)oxy)-beta-methoxy-beta-phenyl-, (S)- 
 

Topic mentions per year

Topic mentions per year

2001-2016
0246820012016

Related topics

Related topics

5 relations

Broader (3)

Endothelin receptor antagonistPhenylpropionatesPyrimidines
LU 127043

Narrower (1)

LU 135252

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
darusentan
Pyrimidines
Phenylpropionates
Endothelin receptor antagonist
LU 135252
LU 127043

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial.
Patients with resistant hypertension are at increased risk for cardiovascular events. The addition of new treatments to existing… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2010
2010
Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.
To evaluate potential mechanisms of clinical hepatotoxicity, 4 endothelin receptor antagonists (ERAs) were examined for substrate… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial.
BACKGROUND Hypertension cannot always be adequately controlled with available drugs. We investigated the blood-pressure-lowering… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2007
2007
Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study.
In this phase 2, randomized, double-blind, placebo-controlled forced dose-titration study, 115 patients with resistant… (More)
Is this relevant?
2006
2006
Up-regulated inflammatory factors endothelin, NFkappaB, TNFalpha and iNOS involved in exaggerated cardiac arrhythmias in l-thyroxine-induced cardiomyopathy are suppressed by darusentan in rats.
The exaggerated cardiac arrhythmias in cardiomyopathy induced by L-thyroxine treatment are related to ion channelopathies and to… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo…
BACKGROUND Endothelin-receptor blockade provides haemodynamic benefit in experimental and clinical heart failure. We aimed to… (More)
Is this relevant?
2002
2002
Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension.
BACKGROUND The antihypertensive efficacy and safety of darusentan, a new selective endothelin, antagonist was investigated… (More)
Is this relevant?
2002
2002
Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT).
BACKGROUND The endothelin (ET-1) system is activated in chronic heart failure (CHF). Whether, what type, and what degree of… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2002
2002
Pharmacological prevention and regression of arterial remodeling in a rat model of isolated systolic hypertension.
OBJECTIVES AND DESIGN Isolated systolic hypertension (ISH) is the predominant form of hypertension in the elderly population and… (More)
Is this relevant?
2002
2002
Treatment with darusentan over 21 days improved cGMP generation in patients with chronic heart failure.
In heart failure, the cGMP to natriuretic peptide ratio is decreased and infusion of atrial natriuretic peptide (ANP) induces… (More)
Is this relevant?